{"name":"Eagle Pharmaceuticals, Inc.","slug":"eagle-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":316610000,"revenueGrowth":84.6,"grossMargin":0,"rdSpend":34088000,"netIncome":35642000,"cash":406160000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ryanodex and Standard of Care","genericName":"Ryanodex and Standard of Care","slug":"ryanodex-and-standard-of-care","indication":"Malignant hyperthermia crisis (acute treatment)","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CAL02","genericName":"CAL02","slug":"cal02","indication":"Treatment of rheumatoid arthritis","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Dantrolene sodium for injectable suspension","genericName":"Dantrolene sodium for injectable suspension","slug":"dantrolene-sodium-for-injectable-suspension","indication":"Malignant hyperthermia","status":"phase_2"}]}],"pipeline":[{"name":"Ryanodex and Standard of Care","genericName":"Ryanodex and Standard of Care","slug":"ryanodex-and-standard-of-care","phase":"phase_3","mechanism":"Ryanodex is a dantrolene sodium formulation that blocks calcium release from the sarcoplasmic reticulum in skeletal muscle by inhibiting the ryanodine receptor.","indications":["Malignant hyperthermia crisis (acute treatment)","Malignant hyperthermia susceptibility (prophylaxis)"],"catalyst":""},{"name":"CAL02","genericName":"CAL02","slug":"cal02","phase":"phase_2","mechanism":"CAL02 is a small molecule that targets the CDK9 enzyme, inhibiting its activity and thereby reducing the expression of inflammatory cytokines.","indications":["Treatment of rheumatoid arthritis"],"catalyst":""},{"name":"Dantrolene sodium for injectable suspension","genericName":"Dantrolene sodium for injectable suspension","slug":"dantrolene-sodium-for-injectable-suspension","phase":"phase_2","mechanism":"Dantrolene sodium works by inhibiting calcium ion release from the sarcoplasmic reticulum, thereby reducing muscle spasticity.","indications":["Malignant hyperthermia","Spinal cord injury","Stroke","Spinal cord injury associated with autonomic dysreflexia","Cerebral palsy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNYjlSNVF6MHJaTHd0eHpYWm52TVd6cWRWLUNMZGFnQS1UeGVwOGI0MnZfUEJHRl93OWFIQ2NhaDFJcl9MeUlScHpXX3NCd0VrUmJvT3A2WmZSa0l3UjlxeU1XdGhCbGhRRWxyZEo2aWlwaFE2MjFvT0dhTDQzd3RHN3B3eTZ3YlI2RW90dnFDMjNpeW1zMG1nUTZFTdIBVkFVX3lxTE1BX0x6anhCNkozM0Y1WExZbzhoaWVrdjc2Y0tqYXQ0RW4tUmM5Q09mcHB1emkwMHl4TjJpbDcydEg5b0doMHVhSC1manBaR0pKampUQkpR?oc=5","date":"2026-03-30","type":"pipeline","source":"Law360","summary":"Eagle Pharma To Pay $9.5M To End Channel Stuffing Claims - Law360","headline":"Eagle Pharma To Pay $9.5M To End Channel Stuffing Claims - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPellmQlE5aURaaXY0ZmkxV3RKalRBZDhvQXM0NnVUV1Y1clpBMWdTZjY3ZjZoWkQtZ1BYbjNROWVBUS1SN3lHWTd0QzNyTm4xeGZ1Z1MwWnZ4NWQzNmlUZVU4Y2ExY2h6ZllQQVhNWG5ucXhVaXRZMkFPZmI3bTM5ZkJLR2s1MjFwb3JYVW9WQnZhR2VDdjVWTndOcXIxeTc4UDcyVDJ6YVNoWmZ5SGl3ZUxCVVpMRE00QlZ6OW1HMkxLaTg?oc=5","date":"2026-01-19","type":"pipeline","source":"AD HOC NEWS","summary":"The Truth About Eagle Pharmaceuticals: Is EGRX the Comeback Story No One Saw Coming? - AD HOC NEWS","headline":"The Truth About Eagle Pharmaceuticals: Is EGRX the Comeback Story No One Saw Coming?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOd05SN1hIYVZvUWNTTENzV1QyZzNJSVZYOVA0aXJPcVNUR2doUnE4MUNVVFg4bHZBTVRlbklUUkxaV2VNOFpkT1NNRnIwQUpFM3M1RWJVYXBEQ2syV0lzckpyaHo0cnp3S0lmU3JtNmhFUjZBUHN4Y29DWmM5c2VYR1d3RFlQajBOb2V3djN3ZlNrVXBMUjROWFZqa1V5YklY?oc=5","date":"2026-01-14","type":"pipeline","source":"Yahoo Finance","summary":"Eagle Pharmaceuticals Announces Divestiture of Barhemsys - Yahoo Finance","headline":"Eagle Pharmaceuticals Announces Divestiture of Barhemsys","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNM09tOFZoZXU0WXpWUU9fMlc4a1hTMkRRWHNZT3hYcF9oY3BoLVJ2a25rNm9IM0g5dm1pRzkzbHNQNDJrX1NsQ1FfZTd1ZnhXbDZTN1FPNTlvd1pVUkhWM2owRmgzWWhTOC1XMktQc19rYzZIdTY0UzZTN2JpeE02ME1DSTNqZW1rNkpzd2JEWjBEVXR4UUtBQ21kNUxpRGdRV1lJ?oc=5","date":"2026-01-14","type":"regulatory","source":"Stock Titan","summary":"Only FDA-approved post-surgery nausea drug shifts to new owner - Stock Titan","headline":"Only FDA-approved post-surgery nausea drug shifts to new owner","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQUkZOamtWZmZmcHBIWmZiSHFEVnN0SlpZUktsZW9NMmk1RTZfaXRqVUNkSzJQY2lUaU1OSk9ualh5ZVFNYnZIUDYyRy1uUE9DM3k3MDVjN2xnWlFMTnBwQ01WbHNZOUpnTC1vdEFjVVktRks1eUxYdTBvajFGdkVZSUZPQUlhQUlheE45TlVkSkdpakk2d0MxOWo4TG5KZS1waWc?oc=5","date":"2025-10-15","type":"earnings","source":"Yahoo Finance","summary":"Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements - Yahoo Finance","headline":"Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPTlhVdi1pNGJfSG1lQ3EwSVdwS1l2M05ET1hlSDV0X0FmbkNOZ0U0dEhoV1pFWXh5Z0htT19qaG15QmhUVEFSZVp0SVhWUUo4Y052ZVVHQ2V6dG41NWRNajBCYmhGMkVIUEdpM1doaW1ISzVCQUJNY0JKMEVBaXhjbzEzUkE3dWN6YnVqY1ZWNjByWV9Ta0c0SXpKV1ZOUTNUaVhIRG9CSjVfWmVvRTYzT1JnLXdzYVJJOGc?oc=5","date":"2025-10-06","type":"earnings","source":"Stock Titan","summary":"Q1 2025 Unaudited Financials — Eagle Pharmaceuticals posts statements and investor materials available now - Stock Titan","headline":"Q1 2025 Unaudited Financials — Eagle Pharmaceuticals posts statements and investor materials available now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOZTFDdzVhdmpNbjRRTDYwWlJHZEFzNjdlLWZYNWRlakdBV3QxOG8xei1uS2p0dmJ0NUh2Y1J0WVRSQ3pjUi1BckYtYVV1X21Qb3BFQUdBQUFvel9UajYycFJ2SHNQT19zMnNjSThlR09zeTRiZzd5NGh4ZndqNU1ocFVPNlFkRExQaUtkdUMzdm9nVjk5NVNtNzJONldtUmhVWXhzRXNn?oc=5","date":"2025-08-08","type":"pipeline","source":"Progressive Grocer","summary":"Giant Eagle Pharmacy Now Part of Mark Cuban Cost Plus Drugs Retailer Network - Progressive Grocer","headline":"Giant Eagle Pharmacy Now Part of Mark Cuban Cost Plus Drugs Retailer Network","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOZFo5d3lobmlVQTJ5Vlh6VjQ4c2Zod0Y0X0hMMlhYUVd3bTFFaGc5aTRRa2dvSTFQaC1UbUZCMmJhVldpb2dPaDh0d3gySjExdThZZTBuV2dhN0RqRjhXVTB4RVl4eU1pRElWV1puYjVqWnBZLUtlczgxbDhaNVNwYmcxWUt3QkF4ZldqRzhCOWVGNU9f?oc=5","date":"2025-08-06","type":"pipeline","source":"WTAE","summary":"'Trying to save everybody money': Giant Eagle and Mark Cuban's Cost Plus Drugs are teaming up - WTAE","headline":"'Trying to save everybody money': Giant Eagle and Mark Cuban's Cost Plus Drugs are teaming up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOVTJUeFBNSVY1WS1tejB4dDFqaW1fa2VmSFBlY1pxLVBMNmtKYTJRek9welNwbTVleF9fRkNhcmZhdE5oLWlMSnRUcWx3Rk1vU21IMUxtbUV5OXJqc0g4Z2o2M0lVNVI1Z2hsTFlxS3dCM1dMMHBYR0FCV2xRWGJPUXEzdHpNMlQzUFhNOFF4bXdoTm5rNzdLNXN0NzZ5RDRld0E1SFVwQWREdlhnWFFoOUVTanFQeVVuRE45THgyWm13bGFVd3Bz?oc=5","date":"2025-07-03","type":"regulatory","source":"PRWeb","summary":"ACA Pharma secures fast-track approval for Eagle Pharmaceuticals' RYANODEX® in Macau - PRWeb","headline":"ACA Pharma secures fast-track approval for Eagle Pharmaceuticals' RYANODEX® in Macau","sentiment":"positive"},{"date":"2024-12-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPNEZkLWlocm05dkYxdWppckk5ZndZY1EzTWFIZDI1NnQtNkxlSjROcXZPeU1Mem5ENkZFVkl6UVJBMml5RHZvdmJkaTlBZU9oaUpHRHRBR2ljenltS1VoSm9DQkQxOHlzUWMwZlNNSS1FU0V1a09CNTNaNFNBei1KYVZzVE15bTdxZmtvcjZZelZUZWNFMnhUa0lxUkEtcUhJcko5WFgxZGFfd1VLLWpCZzJiMG5Ic0RDVFFPQTNpaw?oc=5","date":"2024-11-27","type":"pipeline","source":"Investing.com","summary":"Eagle Pharmaceuticals switches to BDO after Ernst & Young dismissal - Investing.com","headline":"Eagle Pharmaceuticals switches to BDO after Ernst & Young dismissal","sentiment":"neutral"},{"date":"2024-11-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2024-11-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOcXE1WkpoN3ZHUFdDU3J0ZFlmUF8yLXhYVnhYZy04UW1oMThLc2JKd3prZDhKaS02YU50aUNzdXJ1Z2swdVhrMWdwX25pdXlnX2RIRElVc3A5R2sxVV9uOGZ1ZkJnTWNGdzVMMExtSGV2Uzk0aXJOZ09kQ2VnZkFJamJEZVd1bFFVUklMaXBB?oc=5","date":"2022-03-30","type":"pipeline","source":"williamblair.com","summary":"Eagle Pharmaceuticals and Acacia Pharma Transaction - williamblair.com","headline":"Eagle Pharmaceuticals and Acacia Pharma Transaction","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxObGc1MFVfbV93aXRfNEYzMGR0all6TFRKWFV4aURVZGFxWXgxamxIbE9vLUEtQV82V2NZeVdFbXZCOHRkbTRQa1BHWmNHVWlmTnlYUGNjV1hibU1fT3BvWEZ5NWVqV29KY0VTZHJBal94MHJpUEY4VnJBem9MZzlJVnoxM2F5WWROTWE2NDVoNHZHNGwwZzBBaGF4M2xsNXZSd0dkcWtMODBlUldLMGdyYl8zTEVXRTVLcWZwcF9EeWdlcHl0TzF2R05FLWlpZlI1NS1raThoUFpBVDcx?oc=5","date":"2022-03-28","type":"deal","source":"GlobeNewswire","summary":"Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc - GlobeNewswire","headline":"Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":1,"phase_2":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":316610000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":316610000,"period":"2022-12-31"},{"value":171546000,"period":"2021-12-31"},{"value":171546000,"period":"2021-12-31"},{"value":187802000,"period":"2020-12-31"},{"value":187802000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":34088000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":35642000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":406160000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}